ZyVersa Therapeutics has received a notice of intention to grant from the European Patent Office for its patent application for the cholesterol efflux mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin).

The application was filed for the treatment of diabetic nephropathy/diabetic kidney disease.

The Phase IIa-ready VAR 200 is being developed to reduce renal cholesterol and the lipid accumulation that damages the filtration system of kidneys in glomerular diseases patients.

Glomerular diseases include focal segmental glomerulosclerosis, Alport syndrome and diabetic kidney disease.

VAR 200 works by removing the extra lipids from the kidney. It has the potential to reduce proteinuria and to delay the progression of renal disease.

Its lead indication is to treat focal segmental glomerulosclerosis (FSGS), an orphan renal disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ZyVersa Therapeutics co-founder, chairman, CEO and president Stephen Glover stated: “Approval of this patent claiming our cholesterol transport mediator VAR 200 for use in treating diabetic kidney disease speaks to our unique therapeutic approach involving removal of excess cholesterol and lipids that damage the kidneys’ filtration system.

“There are no therapeutic options available that address this issue.

“Strengthening our intellectual property portfolio for VAR 200 and expanding our patent protection and exclusive rights into additional geographic regions will further enable ZyVersa to increase shareholder value as VAR 200 advances into clinical trials, which are planned for initiation in the fourth quarter of this year” (2023).